Travere Therapeutics insider Inrig Jula exercised Options covering 32,395 shares at $8.93 each, then sold 44,674 shares across four transactions priced from $62.02 to $65.31. The disclosure gives investors post-transaction holdings of 145,165 shares after the exercise and 100,491 shares after the sales.
Key Highlights
- Inrig Jula’s post-exercise share position was 145,165.
- Four sales transactions covered 44,674 shares at prices ranging from $62.02 to $65.31.
- The option exercise represented about 42.6% of Jula’s prior derivative-securities holding.
Travere Therapeutics, Inc. is a biotechnology company. Inrig Jula exercised options covering 32,395 shares at $8.93 per share, a transaction that left Jula with 145,165 shares. The transaction took place on 15 September 2026 and carried SEC transaction code M.
Four Share Sales Follow Option Exercise
Transaction code M identifies an option exercise. On the same date, Jula sold 44,674 shares in four separate transactions, with prices spanning $62.02 to $65.31 per share.
Holdings Span Shares and Derivative Securities
The derivative-securities position after the exercise was 43,605, while the transaction represented about 42.6% of Jula’s prior derivative-securities holding. The share exercise represented about 22.3% of the resulting shares holding. The sales represented about 30.8% of Jula’s prior shares holding. The share calculations use different reference points, with the exercise tied to the resulting holding and the sales tied to the prior holding.
FAQs
Q: What price did Inrig Jula pay for the Travere Therapeutics option exercise?
A: The option exercise price was $8.93 per share. It covered 32,395 Travere Therapeutics shares on 15 September 2026 under transaction code M.
Q: How many Travere Therapeutics shares did Inrig Jula sell?
A: Inrig Jula sold 44,674 Travere Therapeutics shares across four transactions. The sales were priced between $62.02 and $65.31 per share on 15 September 2026.
Q: How many shares did Inrig Jula hold after exercising the options?
A: After the exercise, Inrig Jula held 145,165 shares of Travere Therapeutics. The exercise represented about 22.3% of the resulting shares holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.